Background: Human Parvovirus B19 (PB19) is one of the smallest viruses that infect human erythroid progenitor cells, causing a sudden cessation of erythrocyte production. Infection with PB19 may precede the development of acute leukaemia and worsen the case of those patients. PB19 constitutes a high risk for this group of patients.

Objective: Screening patients with acute leukemias for anti-human Parvovirus B19 antibodies

Methods: 75 blood samples of acute leukaemia patients and 75 blood samples of healthy individuals recruited from Suez Canal University Hospital were screened for antihuman parvovirus B19 IgM and antihuman parvovirus B19 IgG antibodies by implementing ELISA technique.

Results: The prevalence of antihuman parvovirus B19 IgM and IgG antibodies in patients with acute leukaemia 22.7% and 98.7% respectively. The prevalence of IgG antibodies against human parvovirus B19 within the control group was 14.7%.

Conclusion: This study reported the presence of both types of anti-human parvovirus B19 IgM and IgG antibodies in patients with acute leukemias in Suez Canal University hospital which constitutes a high risk for acute leukemia patients and worsen their clinical blood parameters as well.